No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AEON AEON Biopharma
- 1.770
- +0.180+11.32%
Close May 8 16:00 ET
- 1.940
- +0.170+9.60%
Post 19:59 ET
68.65MMarket Cap-1796P/E (TTM)
1.800High1.580Low130.58KVolume1.580Open1.590Pre Close223.88KTurnover0.88%Turnover RatioLossP/E (Static)38.78MShares17.17052wk High-0.45P/B26.33MFloat Cap1.38052wk Low--Dividend TTM14.87MShs Float17.170Historical High--Div YieldTTM13.84%Amplitude1.380Historical Low1.714Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
AEON Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 990.91% HC Wainwright & Co. → $18 Reiterates Buy → Buy 04/17/2024 990.91% HC Wainwright & Co. →
Maintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 Setback
US Equity Markets Close Higher Friday Following Weak Jobs Report
US equity markets ended higher Friday after a weak jobs report raised bets on interest rate cuts. * Nonfarm payrolls rose by 175,000 in April, well below expectations for an increase of 240,000 jobs,
Ardelyx ARDX Earnings; AEON Biopharma AEON Phase 2 Fail
Sector Update: Health Care
Health care stocks were mixed late Friday afternoon with the NYSE Health Care Index shedding 0.2% and the Health Care Select Sector SPDR Fund (XLV) rising 0.2%. The iShares Biotechnology ETF (IBB) cli
Comments
$AEON Biopharma(AEON.US$
this is depressing. wonder will the counter just get itself delisted from the market? people just treat the compat withour any single hope?
![]()
this is depressing. wonder will the counter just get itself delisted from the market? people just treat the compat withour any single hope?
3
6
this is a buy for me, 5 leg was basically already completed before this negative news and had been in a downtrend since mid March
4
5
$AEON Biopharma(AEON.US$
NEWS
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AEON Biopharma announced that the preliminary results from the Phase 2 trial with ABP-450 for chronic migraine prevention did not meet the primary endpoint of mean reduction in monthly migraine days. The trial showed no statistical significance in reduction compared to placebo, leading to the company initiating cash preserva...
NEWS
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AEON Biopharma announced that the preliminary results from the Phase 2 trial with ABP-450 for chronic migraine prevention did not meet the primary endpoint of mean reduction in monthly migraine days. The trial showed no statistical significance in reduction compared to placebo, leading to the company initiating cash preserva...
3
1
$AEON Biopharma(AEON.US$ Press Release: AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
Dow Jones· 5 mins ago
Dow Jones· 5 mins ago
1
$AEON Biopharma(AEON.US$ AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
1 MINUTE AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –
– An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are e...
1 MINUTE AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –
– An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are e...
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
70927684 : What Happen???
BSDLuckyOP 70927684: Their trial candidate failed.
70927684 : LFG!!! Historical Low Play !!! Hornahha !!!!
70927684 : DP IT!!!
70927684 : LFG!!!!!!!!!!!!!!!!
View more comments...